AZALIA® – Bioequivalent to Cerazette®

A package of Azalia contraceptives

  • Contains 75μg desogestrel and no oestrogen, exactly the same active ingredient as Cerazette®¹-²
  • AZALIA® is GMS Reimbursed
  • Oestrogen-free progestogen-only contraceptive pill¹
  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive with no oestrogen¹
  • Inhibits ovulation and increases the viscosity of the cervical mucus¹
  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly¹-⁴
  • AZALIA® has a Pearl Index of 0.4¹
  • Side effects associated with combined oral contraceptives may be reduced or ameliorated by taking an oestrogen-free pill such as AZALIA®⁴
  • Side effects may include depressed mood and depression.
  • In a clinical trial 85–87% of women indicated that they would continue to use 75μg desogestrel at the end of the trial⁴
  • AZALIA® has a 12-hour missed pill window¹
  • AZALIA® is taken continuously as a 28 day treatment regime¹

AZALIA® is suitable for use in the following patient groups:⁵-⁶

  • Women of all ages including breast feeding women
  • Women with a BMI of ≥35 kg/m2
  • Women who smoke
  • Women who experience oestrogen-related side effects on COCs
  • Women who suffer from hypertension
  • Women with a family history of venous thromboembolism
  • Women with endometriosis


1. Azalia® SmPC
2. Cerazette® SmPC
available at
3. MIMS Ireland (August 2017) ‘Contraception’ MPI Media Ltd, Dublin.
4. Ahrendt HJ, Karckt U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from
two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007; 12(4): 354–361.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
6. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.

IE/OCS/0817/0058b Date of preparation: July 2018

Web design by

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.